Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia.
School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
Diabetologia. 2023 Jul;66(7):1223-1234. doi: 10.1007/s00125-023-05897-5. Epub 2023 Mar 18.
AIMS/HYPOTHESIS: The aim of this study was to determine the long-term cost-effectiveness and return on investment of implementing a structured lifestyle intervention to reduce excessive gestational weight gain and associated incidence of gestational diabetes mellitus (GDM) and type 2 diabetes mellitus.
A decision-analytic Markov model was used to compare the health and cost-effectiveness outcomes for (1) a structured lifestyle intervention during pregnancy to prevent GDM and subsequent type 2 diabetes; and (2) current usual antenatal care. Life table modelling was used to capture type 2 diabetes morbidity, mortality and quality-adjusted life years over a lifetime horizon for all women giving birth in Australia. Costs incorporated both healthcare and societal perspectives. The intervention effect was derived from published meta-analyses. Deterministic and probabilistic sensitivity analyses were used to capture the impact of uncertainty in the model.
The model projected a 10% reduction in the number of women subsequently diagnosed with type 2 diabetes through implementation of the lifestyle intervention compared with current usual care. The total net incremental cost of intervention was approximately AU$70 million, and the cost savings from the reduction in costs of antenatal care for GDM, birth complications and type 2 diabetes management were approximately AU$85 million. The intervention was dominant (cost-saving) compared with usual care from a healthcare perspective, and returned AU$1.22 (95% CI 0.53, 2.13) per dollar invested. The results were robust to sensitivity analysis, and remained cost-saving or highly cost-effective in each of the scenarios explored.
CONCLUSIONS/INTERPRETATION: This study demonstrates significant cost savings from implementation of a structured lifestyle intervention during pregnancy, due to a reduction in adverse health outcomes for women during both the perinatal period and over their lifetime.
目的/假设:本研究旨在确定实施结构化生活方式干预以减少过度妊娠体重增加及相关妊娠糖尿病(GDM)和 2 型糖尿病发病率的长期成本效益和投资回报。
使用决策分析马尔可夫模型比较(1)怀孕期间进行结构化生活方式干预以预防 GDM 及随后的 2 型糖尿病;以及(2)目前的常规产前护理。寿命表模型用于在澳大利亚所有分娩妇女的一生中捕获 2 型糖尿病的发病率、死亡率和质量调整生命年。成本包括医疗保健和社会两个方面。干预效果源自已发表的荟萃分析。确定性和概率敏感性分析用于捕捉模型不确定性的影响。
该模型预测,与目前的常规护理相比,通过实施生活方式干预,随后诊断为 2 型糖尿病的女性人数将减少 10%。干预的总净增量成本约为 7000 万澳元,通过减少 GDM、分娩并发症和 2 型糖尿病管理的产前护理成本,可节省约 8500 万澳元。从医疗保健角度来看,干预具有成本效益(节省成本),与常规护理相比,每投资 1 澳元可获得 1.22 澳元(95%CI 0.53,2.13)的回报。结果对敏感性分析具有稳健性,在每个探索的情景中均保持成本效益或具有高度成本效益。
结论/解释:本研究表明,由于在围产期和整个生命周期内,女性的不良健康结果减少,因此实施结构化生活方式干预可带来显著的成本节约。